We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > liver cancer treatment

News List

Rexahn, Haichang collaborate for developing liver cancer treatment biospectrumasia
February 11, 2018
Any clinical trials conducted by Haichang will be designed to meet both U.S. and Chinese regulatory requirements.
EU approved Bayer's Stivarga for the Second-Line Systemic Treatment of Liver Cancer firstwordpharma
August 08, 2017
The approval for the first treatment advance in nearly 10 years is based on data from the Phase III RESORCE research.
FDA awards priority review to Bayer's filing for Stivarga as second-line liver cancer treatment firstwordpharma
January 05, 2017
Bayer on Wednesday said the FDA granted priority review to an application seeking approval of Stivarga (regorafenib) for the second-line treatment of patients with hepatocellular carcinoma (HCC).